Vytorin news from FiercePharma
News
Cholesterol drug market shifts
Big-name cholesterol meds are losing ground on two fronts. First, the Pfizer cholesterol drug Lipitor--its Read more...
AMA calls for tighter DTC regulation
We all expected Democrats to rake DTC ads over the coals during yesterday's hearing before the House Energy and Commerce Committee's oversight arm. We expected Chairman Bart Stupak to call for Read more...
Will DTC hearing lead to new regulation?
Will today's Congressional hearing on drug ads lead to new legislation? That's what Michigan Read more...
U.S. Attys probe Schering over Vytorin
The ranks of investigators probing Schering-Plough and its Vytorin drug are broadening. In a recent SEC filing, Schering disclosed that U.S. Attorneys have been asking for info and documents related Read more...
Merck to cut 1,200 sales reps
The axeman cometh to Merck's sales force. The drugmaker plans to lop off about 15 percent in the sales ranks, or 1,200 jobs. The fact that it's not alone in trimming back on reps--Wyeth just Read more...
Merck CEO: 'I can't blame the media'
A triad of Merck news today, including one item about the news. We'll start with that: CEO Dick Clark (photo) Read more...
Where Merck loses, Abbott gains
What's bad for Merck is good for Abbott Labs. When the FDA said "no" to Read more...
Fissures in Merck, Schering relationship?
Are fault lines in the Merck/Schering-Plough joint venture beginning to open up? Market-watchers are reading the earnings-call transcripts--and the tea leaves--and finding evidence of "the Read more...
Pharma CEOs mull industry "trust deficit'
We love it when pharma CEOs depart from their usual talking points about financial results and restructurings and pipelines, to wax philosophical on their place in the word. This week, we heard an Read more...
Hassan gets $30M pay package
Fred Hassan (photo) may have his hands full these days, defending Vytorin and Zetia while cutting jobs and costs. But Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight